Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Alder Bioph (ALDR_old)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Alder Bioph's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
Alder Bioph historical data, for real-time data please try another search
18.88 0.00    0.00%
04/02 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 0
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 18.82 - 19.12
Alder Bioph 18.88 0.00 0.00%

Alder Bioph Company Profile

 
Get an in-depth profile of Alder Bioph, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

202

Equity Type

ORD

Lundbeck Seattle BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercialized therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. Its product includes, eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Lundbeck Seattle BioPharmaceuticals, Inc. was formerly known as Alder Biopharmaceuticals, Inc. and changed its name to Lundbeck Seattle BioPharmaceuticals, Inc. in November 2019. The company was founded in 2002 and is based in Bothell, Washington. As of October 22, 2019, Lundbeck Seattle BioPharmaceuticals, Inc. operates as a subsidiary of H. Lundbeck A/S.

Contact Information

Address 11804 North Creek Parkway South
Bothell, 98011-8801
United States
Phone 425 205 2900
Fax 425 205 2901
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ALDR_old Comments

Write your thoughts about Alder Bioph
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Ivan Projic
Ivan Projic Sep 16, 2019 10:51AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
+83.10% what???
Episcopolian OptionTrader
Episcopolian1 Oct 05, 2017 2:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$ALDR Finally 10 weeks SMA is crossing over the 50 weeks SMA! . What does it mean? It is time to buy and hold!
Seth Rudnick
Seth Rudnick Oct 05, 2017 2:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How high of a target do you predict?
andrew mccorkle
andrew mccorkle Oct 05, 2017 2:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
kip jo jo no no no
Episcopolian OptionTrader
Episcopolian1 Jun 27, 2017 9:28AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This is a great  entry point BUY" for $ALDR. Data was "excellent: and it is quite frankly a "take-out" target for a big phama!
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email